BioSpace News Archive

Rhythmlink International, LLC is pleased to announce an exciting new investment, the acquisition of Chalgren Enterprises, a California-based medical device manufacturer that will add to their already extensive portfolio of products for brain and nervous system monitoring.

Apollo Endosurgery, Inc. (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today U.S. Food and Drug Administration 510k clearance of the X-Tack; Endoscopic HeliX Tacking System. X-Tack is a new, through-the-scope, suture-based device designed specifically for closing and healing defects in the lower gastrointestinal tract

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood)

Novartis today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 that the data presented support the use of Entresto® (sacubitril/valsartan) in treatment of patients with heart failure with preserved ejection fraction (HFpEF).

BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial public offering of 10,500,000 shares of common stock at a public offering price of $18.00 per share.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today held an R&D virtual event to provide an update on the latest progress for its clinical pipeline.

Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $58.00 per share.

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces an amendment to the terms of its investment agreement with Cosmo Technologies Ltd, a wholly-owned subsidiary of Cosmo Pharmaceuticals N.V.

The global market for rehabilitation equipment has been growing alongside the need to improve the quality of life of disabled, elderly, or sick persons.

An apheresis machine comprises of a gadget or device which gathers blood removed from the body of the donor and separates it into the diverse components, for instance, platelets, plasma, platelets, red and white platelets.